文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

依达赛珠单抗推荐剂量反应不完全:系统评价与药代动力学分析

Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
PubMed 文献 · Clin Toxicol (Phila) · 2020-04-08
一句话结论达比加群浓度>228 ng/mL或GFR<30 mL/min者,5 g依达赛珠单抗后中位22小时可出现浓度反跳;作者建议给药后至少36小时内每6小时监测凝血与达比加群浓度。

该系统评价检索PubMed 2015年至2019年10月共387条记录,最终从97篇文献提取数据,纳入240例接受依达赛珠单抗的已发表病例。33例报告达比加群浓度反跳,中位时间22小时;231例报告剂量者中10例因浓度反跳接受重复给药。基线达比加群>228 ng/mL更易反跳至>30 ng/mL(可检测),>488 ng/mL反跳至>75 ng/mL(治疗水平)。药代动力学模拟提示,达比加群150 mg每日两次者,GFR<30 mL/min约72小时给药后、GFR 6 mL/min约36小时给药后预测对5 g依达赛珠单抗反应不完全。作者建议给药后至少36小时内每6小时检测凝血与达比加群浓度,尤其GFR<30 mL/min或达比加群浓度>约500 ng/mL者;若反跳,临床需要时可考虑重复5 g依达赛珠单抗。

要点

  • 240例接受依达赛珠单抗的病例中33例出现达比加群浓度反跳,中位时间22小时。
  • 基线达比加群>228 ng/mL更易反跳至>30 ng/mL(可检测);>488 ng/mL反跳至>75 ng/mL(治疗水平)。
  • 作者建议依达赛珠单抗给药后至少36小时内每6小时检测凝血和达比加群浓度以发现反跳。
  • GFR<30 mL/min或达比加群浓度>约500 ng/mL者尤其需要监测反跳。
  • 若发现达比加群反跳,临床需要时可考虑重复给予依达赛珠单抗5 g以逆转复发的凝血障碍。

适用人群与场景

  • 接受达比加群抗凝、需依达赛珠单抗逆转的已发表病例,包括急性或慢性肾脏病患者。
  • 故意达比加群自我中毒者:依达赛珠单抗在有限病例中已中和达比加群,即使无出血;作为标准支持治疗一部分的数据不足。

诊断标准与关键阈值

  • 基线达比加群浓度>228 ng/mL更易在依达赛珠单抗后反跳至>30 ng/mL(可检测)。
  • 基线达比加群浓度>488 ng/mL反跳至>75 ng/mL(治疗水平)。
  • 稀释凝血酶时间可用于测定达比加群浓度,其他更标准的凝血试验精确度较低;正常aPTT基本可排除达比加群。

处置流程与药物剂量

  • 依达赛珠单抗标准剂量为5 g。
  • 作者建议依达赛珠单抗给药后至少36小时内每6小时进行凝血试验和达比加群浓度检测以发现反跳。
  • GFR<30 mL/min或血浆达比加群浓度>约500 ng/mL者尤其需要上述监测。
  • 若发现达比加群反跳,临床需要时可考虑重复给予依达赛珠单抗5 g以逆转复发的凝血障碍。

红旗征与不能漏的情况

  • 依达赛珠单抗后达比加群浓度反跳(中位22小时),可导致治疗失败。
  • 肾功能严重受损者(GFR<30 mL/min)预测对5 g依达赛珠单抗反应不完全。

研究设计与关键结果

  • 系统评价:PubMed检索2015年至2019年10月,387条记录,97篇合格文献提取数据,纳入240例接受依达赛珠单抗的已发表病例。
  • 240例中33例报告达比加群浓度反跳,中位时间22小时;231例报告依达赛珠单抗剂量者中10例因浓度反跳接受重复给药。
  • 基线达比加群>228 ng/mL更易反跳至>30 ng/mL(可检测);>488 ng/mL反跳至>75 ng/mL(治疗水平)。
  • 药代动力学模拟:依达赛珠单抗预期最多中和血浆达比加群浓度980 ng/mL,但实际很可能更低。
  • 药代动力学模拟:达比加群150 mg每日两次者,GFR<30 mL/min(正常的25%)约72小时给药后、GFR 6 mL/min(正常的5%)约36小时给药后,预测对5 g依达赛珠单抗反应不完全。

证据类型、等级与局限

  • 证据类型:系统评价结合药代动力学模拟分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议依达赛珠单抗给药后至少36小时内每6小时检测凝血和达比加群浓度以发现反跳,尤其GFR<30 mL/min或达比加群浓度>约500 ng/mL者。
  • 作者认为若发现达比加群反跳,临床需要时可考虑重复给予依达赛珠单抗5 g。
  • 稀释凝血酶时间可用于测定达比加群浓度,其他更标准凝血试验精确度较低;正常aPTT基本可排除达比加群。
  • 故意达比加群自我中毒时使用依达赛珠单抗作为标准支持治疗一部分的数据不足。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: Dabigatran, a direct thrombin inhibitor, is 80% renally eliminated and demonstrates multi-compartmental pharmacokinetics. Idarucizumab is a monoclonal antibody that reverses dabigatran-induced anticoagulation and displays single compartment pharmacokinetics, with a smaller volume of distribution and shorter elimination half-life than dabigatran. These differences in pharmacokinetics mean that redistribution of dabigatran from peripheral compartments can occur after idarucizumab has been eliminated, resulting in rebound in the dabigatran plasma concentration and treatment failure. Clinical experience notes failure of a single idarucizumab 5 g dose to fully reverse coagulopathy in certain patients.Aims: To identify factors predisposing to an incomplete response to the standard idarucizumab 5 g dose.Methods: A systematic literature search in PubMed using terms "dabigatran" and "idarucizumab" covering 2015 to October 2019 identified 387 entries. Titles and abstracts were screened initially, followed by full text review and data extraction from 97 eligible articles. Data extracted included clinical information, dabigatran concentrations, coagulation results, idarucizumab dosage and patient outcomes. Pharmacokinetic simulations were conducted using a two-compartment model to predict the likelihood that acute or chronic kidney disease will contribute to an incomplete reversal of dabigatran-induced anticoagulation.Results: Of 240 published cases receiving idarucizumab, 33 reported dabigatran concentration rebound, within a median time of 22 h. From 231 cases reporting idarucizumab dose, 10 received repeated administration due to a rebound in dabigatran concentrations. Baseline dabigatran concentrations >228 ng/mL were more likely to experience a rebound post-idarucizumab to >30 ng/mL (detectable). For baseline dabigatran >488 ng/mL, the concentration rebounded to >75 ng/mL (therapeutic). The impact of kidney dysfunction on the effect of the recommended dose of idarucizumab: Idarucizumab is expected to neutralise a maximum plasma dabigatran concentration of 980 ng/mL, but most likely a lesser amount. Pharmacokinetic modelling suggests, for patients taking dabigatran 150 mg twice daily, an incomplete response to 5 g idarucizumab is predicted after approximately 72 h dosing when GFR less than 30 mL/min (25% of normal), and after 36 h with severely impaired renal function (GFR 6 mL/min; GFR 5% of normal). Acute dabigatran self-poisoning: Idarucizumab has neutralised dabigatran following deliberate self-poisoning with dabigatran in a limited number of cases, even in the absence of bleeding. There are insufficient data regarding the use of idarucizumab as part of standard supportive care in this context. Clinical use of idarucizumab in complex circumstances: The dilute thrombin time can be used to determine the dabigatran concentration, but other more standard coagulation assays are less precise. A normal aPTT largely excludes dabigatran. We suggest performing coagulation assays and dabigatran concentrations every 6 h for a minimum of 36 h after idarucizumab administration to detect a rebound in dabigatran. This is particularly necessary in patients with glomerular filtration rate <30 mL/min or those with a plasma dabigatran concentration exceeding approximately 500 ng/mL. If a rebound in dabigatran is noted, then repeat administration of idarucizumab 5 g can be considered for reversal of recurrent coagulopathy if clinically indicated.Conclusion: The use of idarucizumab for reversal of dabigatran is complex and requires consideration of clinical circumstances and laboratory investigations. Monitoring post-idarucizumab may be required in acute or chronic kidney disease to detect a rebound in dabigatran concentration and the need for additional doses of idarucizumab.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Athavale A, Jamshidi N, Roberts DM, et al. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clin Toxicol (Phila). 2020. PMID: 32267185. doi:10.1080/15563650.2020.1743846

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。